Fig. 1: Clinical outcomes by FLT3-TKD MRD status. | Bone Marrow Transplantation

Fig. 1: Clinical outcomes by FLT3-TKD MRD status.

From: Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia

Fig. 1

Rates of (a) relapse and (b) overall survival for patients based on the presence (MRDpos) or absence (MRDneg) of residual FLT3 tyrosine kinase domain (TKD) variants in pre-transplant blood. FLT3-TKD MRDpos patients were divided by the level of residual disease based on variant allele fraction (VAF) above or below 0.1%. Survival curves plotted using the Kaplan-Meier estimator and compared with the log-rank test and cumulative incidence of relapse plotted using the cumulative incidence function and compared with Gray’s test.

Back to article page